Santhera Pharmaceuticals Holding AG (0QN1.L)
CHF 9.79
(-0.81%)
CHF 9.79
(-0.81%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 109.62 Million CHF | 72.03% |
| 2022 | 63.72 Million CHF | -30.06% |
| 2021 | 91.11 Million CHF | 2.74% |
| 2020 | 88.68 Million CHF | -22.92% |
| 2019 | 115.05 Million CHF | 4.31% |
| 2018 | 110.29 Million CHF | 0.47% |
| 2017 | 109.78 Million CHF | 20.91% |
| 2016 | 90.79 Million CHF | -22.5% |
| 2015 | 117.15 Million CHF | 410.58% |
| 2014 | 22.94 Million CHF | 135.67% |
| 2013 | 9.73 Million CHF | -46.75% |
| 2012 | 18.28 Million CHF | -64.86% |
| 2011 | 52.03 Million CHF | -33.94% |
| 2010 | 78.76 Million CHF | -16.83% |
| 2009 | 94.7 Million CHF | -16.15% |
| 2008 | 112.94 Million CHF | -21.66% |
| 2007 | 144.17 Million CHF | -11.22% |
| 2006 | 162.39 Million CHF | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 108.24 Million CHF | 0.0% |
| 2024 Q1 | 108.24 Million CHF | -1.26% |
| 2023 Q1 | 63.07 Million CHF | -1.02% |
| 2023 FY | 109.62 Million CHF | 72.03% |
| 2023 Q3 | 109.62 Million CHF | 73.81% |
| 2023 Q2 | 63.07 Million CHF | 0.0% |
| 2023 Q4 | 109.62 Million CHF | 0.0% |
| 2022 Q2 | 79.78 Million CHF | 0.0% |
| 2022 Q4 | 63.72 Million CHF | 0.0% |
| 2022 FY | 63.72 Million CHF | -30.06% |
| 2022 Q1 | 79.78 Million CHF | -12.44% |
| 2022 Q3 | 63.72 Million CHF | -20.12% |
| 2021 Q3 | 91.11 Million CHF | 13.59% |
| 2021 FY | 91.11 Million CHF | 2.74% |
| 2021 Q1 | 80.21 Million CHF | -9.55% |
| 2021 Q2 | 80.21 Million CHF | 0.0% |
| 2021 Q4 | 91.11 Million CHF | 0.0% |
| 2020 Q1 | 100.07 Million CHF | -13.02% |
| 2020 Q2 | 100.07 Million CHF | 0.0% |
| 2020 FY | 88.68 Million CHF | -22.92% |
| 2020 Q4 | 88.68 Million CHF | 0.0% |
| 2020 Q3 | 88.68 Million CHF | -11.38% |
| 2019 Q3 | 115.05 Million CHF | 8.44% |
| 2019 Q1 | 106.09 Million CHF | -3.81% |
| 2019 FY | 115.05 Million CHF | 4.31% |
| 2019 Q4 | 115.05 Million CHF | 0.0% |
| 2019 Q2 | 106.09 Million CHF | 0.0% |
| 2018 Q2 | 92.15 Million CHF | 0.0% |
| 2018 Q1 | 92.15 Million CHF | -16.06% |
| 2018 FY | 110.29 Million CHF | 0.47% |
| 2018 Q4 | 110.29 Million CHF | 40.02% |
| 2018 Q3 | 78.77 Million CHF | -14.52% |
| 2017 Q4 | 109.78 Million CHF | 0.0% |
| 2017 FY | 109.78 Million CHF | 20.91% |
| 2017 Q2 | 130.15 Million CHF | 0.0% |
| 2017 Q1 | 130.15 Million CHF | 43.35% |
| 2016 Q4 | 90.79 Million CHF | 0.0% |
| 2016 FY | 90.79 Million CHF | -22.5% |
| 2016 Q2 | 104.88 Million CHF | 0.0% |
| 2016 Q3 | 90.79 Million CHF | -13.43% |
| 2016 Q1 | 104.88 Million CHF | -10.48% |
| 2015 Q3 | 117.15 Million CHF | 514.78% |
| 2015 Q2 | 19.05 Million CHF | 0.0% |
| 2015 Q1 | 19.05 Million CHF | -16.95% |
| 2015 FY | 117.15 Million CHF | 410.58% |
| 2015 Q4 | 117.15 Million CHF | 0.0% |
| 2014 Q2 | 9.87 Million CHF | 0.0% |
| 2014 Q1 | 9.87 Million CHF | 1.41% |
| 2014 FY | 22.94 Million CHF | 135.67% |
| 2014 Q3 | 23.02 Million CHF | 133.18% |
| 2014 Q4 | 22.94 Million CHF | -0.33% |
| 2013 Q3 | 9.73 Million CHF | -21.96% |
| 2013 Q4 | 9.73 Million CHF | 0.0% |
| 2013 FY | 9.73 Million CHF | -46.75% |
| 2013 Q1 | 12.47 Million CHF | -31.77% |
| 2013 Q2 | 12.47 Million CHF | 0.0% |
| 2012 Q4 | 18.28 Million CHF | 0.0% |
| 2012 Q3 | 18.28 Million CHF | -59.42% |
| 2012 FY | 18.28 Million CHF | -64.86% |
| 2012 Q2 | 45.06 Million CHF | 0.0% |
| 2011 FY | 52.03 Million CHF | -33.94% |
| 2011 Q2 | 65.36 Million CHF | 0.0% |
| 2011 Q4 | 52.03 Million CHF | 0.0% |
| 2010 Q4 | 78.76 Million CHF | 0.0% |
| 2010 FY | 78.76 Million CHF | -16.83% |
| 2010 Q2 | 77.41 Million CHF | 0.0% |
| 2009 FY | 94.7 Million CHF | -16.15% |
| 2009 Q4 | 94.7 Million CHF | 0.0% |
| 2008 FY | 112.94 Million CHF | -21.66% |
| 2007 FY | 144.17 Million CHF | -11.22% |
| 2006 FY | 162.39 Million CHF | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Relief Therapeutics Holding AG | 76.39 Million CHF | -43.512% |
| Tecan Group AG | 2.07 Billion CHF | 94.714% |
| Basilea Pharmaceutica AG | 173.28 Million CHF | 36.736% |
| Bachem Holding AG | 1.68 Billion CHF | 93.486% |
| Siegfried Holding AG | 1.86 Billion CHF | 94.111% |
| Molecular Partners AG | 198.35 Million CHF | 44.73% |